![Jeffery Errington](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jeffery Errington
Gründer bei Demuris Ltd.
Aktive Positionen von Jeffery Errington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Demuris Ltd.
![]() Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Direktor/Vorstandsmitglied | 03.09.2007 | - |
Vorstandsvorsitzender | 22.05.2007 | - | |
Gründer | 22.05.2007 | - |
Karriereverlauf von Jeffery Errington
Ehemalige bekannte Positionen von Jeffery Errington
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BIOTA HOLDINGS LTD. | Direktor/Vorstandsmitglied | 02.02.2010 | 12.08.2013 |
Independent Dir/Board Member | 01.02.2010 | 12.08.2013 | |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Direktor/Vorstandsmitglied | 09.11.2012 | 12.08.2013 |
The University of Newcastle | Corporate Officer/Principal | 28.01.2011 | - |
University of Oxford | Corporate Officer/Principal | - | - |
Prolysis Ltd.
![]() Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Direktor/Vorstandsmitglied | - | - |
Technik-/Wissenschafts-/F&E-Leiter | - | - | |
Gründer | - | - |
Ausbildung von Jeffery Errington
University of Oxford | Graduate Degree |
The University of Newcastle | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 4 |
Australien | 3 |
Vereinigte Staaten | 2 |
Operativ
Director/Board Member | 4 |
Founder | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Distribution Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Prolysis Ltd.
![]() Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Health Technology |
Biota Holdings Pty Ltd.
![]() Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Demuris Ltd.
![]() Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Distribution Services |
Aviragen Therapeutics, Inc.
![]() Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Börse
- Insiders
- Jeffery Errington
- Erfahrung